Ardelyx chops a third of its staff after stock-crushing failure in chronic kidney disease

A couple of weeks after the FDA turned down Ardelyx’s chronic kidney disease candidate, shocking analysts and CEO Mike Raab, the company is axing 33% of its employees to deal with the loss.